VRS
ARQT icon

Virginia Retirement Systems’s Arcutis Biotherapeutics ARQT Stock Holding History

Virginia Retirement Systems’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,250
Closed -$414K – 943
2025
Q4 		$414K Buy
+14,250
New +$365K ﹤0.01% 795
2023
Q3 		$157K Buy
+29,500
New +$251K ﹤0.01% 897

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virginia Retirement Systems's ARQT Position: Q1 2026 in Review

Virginia Retirement Systems sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 14,250 shares — an estimated $414K sold.

Virginia Retirement Systems first reported a position in ARQT in Q3 2023 and held it in 2 quarters. The position peaked at $414K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Virginia Retirement Systems reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Virginia Retirement Systems sold 14,250 Arcutis Biotherapeutics shares in Q1 2026, an estimated $414K.
  • Virginia Retirement Systems first reported a position in Arcutis Biotherapeutics in Q3 2023 and held it in 2 quarters.
  • Virginia Retirement Systems's Arcutis Biotherapeutics position peaked at $414K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Virginia Retirement Systems's 13F filing for Q1 2026, filed 25 Aug 2026.